IP Library Granted Patent US 9,441,216
Granted Patent B2
US 9,441,216 · App. 14/807,745 · Granted Sep 13, 2016

Cell culture medium for ADAMTS protein expression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,441,216
App. No.
14/807,745
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.

Claims (26)

1. A method for expressing a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) protein, the method comprising culturing a cell harboring a nucleic acid encoding an ADAMTS13 protein in a culture medium comprising from 3 μM to 12 μM zinc and at least 2 mg/L nicotinamide,

wherein the ADAMTS13 protein expressed according to the method has a greater specific activity as compared to an ADAMTS13 protein expressed in culture medium comprising 1.5 μM zinc.

2. The method of claim 1 , wherein the culture medium comprises at least 4 mg/L nicotinamide.

3. The method of claim 1 , wherein the culture medium comprises at least 6 mg/L nicotinamide.

4. The method of claim 1 , wherein the culture medium comprises from 2 mg/L to 10 mg/L nicotinamide.

5. The method of claim 1 , wherein the culture medium comprises from 4 mg/L to 10 mg/L nicotinamide.

6. The method of claim 1 , wherein the culture medium further comprises from 0.5 mM to 1.5 mM calcium.

7. The method of claim 2 , wherein the culture medium further comprises from 0.5 mM to 1.5 mM calcium.

8. The method of claim 3 , wherein the culture medium further comprises from 0.5 mM to 1.5 mM calcium.

9. The method of claim 4 , wherein the culture medium further comprises from 0.5 mM to 1.5 mM calcium.

10. The method of claim 5 , wherein the culture medium further comprises from 0.5 mM to 1.5 mM calcium.

11. The method of claim 1 , wherein the culture medium further comprises at least 1.0 mM calcium.

12. The method of claim 2 , wherein the culture medium further comprises at least 1.0 mM calcium.

13. The method of claim 3 , wherein the culture medium further comprises at least 1.0mM calcium.

14. The method of claim 4 , wherein the culture medium further comprises at least 1.0 mM calcium.

15. The method of claim 5 , wherein the culture medium further comprises at least 1.0 mM calcium.

16. The method of claim 1 , wherein the cell is a mammalian cell line selected from the group consisting of a human cell line, a hamster cell line, and a murine cell line.

17. The method of claim 4 , wherein the cell is a mammalian cell line selected from the group consisting of a human cell line, a hamster cell line, and a murine cell line.

18. The method of claim 5 , wherein the cell is a mammalian cell line selected from the group consisting of a human cell line, a hamster cell line, and a murine cell line.

19. The method of claim 9 , wherein the cell is a mammalian cell line selected from the group consisting of a human cell line, a hamster cell line, and a murine cell line.

20. The method of claim 10 , wherein the cell is a mammalian cell line selected from the group consisting of a human cell line, a hamster cell line, and a murine cell line.

21. The method of claim 1 , wherein the ADAMTS13 protein is a human ADAMTS13 protein.

22. The method of claim 4 , wherein the ADAMTS13 protein is a human ADAMTS13 protein.

23. The method of claim 16 , wherein the ADAMTS13 protein is a human ADAMTS13 protein.

24. The method of claim 17 , wherein the ADAMTS13 protein is a human ADAMTS13 protein.

25. The method of claim 19 , wherein the ADAMTS13 protein is a human ADAMTS13 protein.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: GRILLBERGER, LEOPOLD; SPENGER, ALEXANDRA; HASSLACHER, MEINHARD; GRILLBERGER, RANA; REITER, MANFRED
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 039372/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 039630/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 039630/0465 →